A pivotal trial of MT-3724 in pateints with non-Hodgkin's Lymphoma (NHL)
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2017
At a glance
- Drugs MT 3724 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- 30 Mar 2017 According to a Molecular Templates media release, the company expects to initiate this trial before the end of 2017.
- 25 Mar 2017 New trial record
- 17 Mar 2017 According to a Threshold Pharmaceuticals media release, Threshold Pharmaceuticals and Molecular Templates Agree to Combine and Combined company will be capitalized to support advancement of this trial.